TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02925650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posiphen
Description: oral solid dosage form capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posiphen
Description: oral solid dosage form capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posiphen
Description: oral solid dosage form capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral solid dosage form capsule
Study: NCT03283033

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New salad bar
Description: New salad bar placed in school

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New salad bar
Description: New salad bar placed in school

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Marketing
Description: Marketing conditions (printed material, displays, verbal announcements, prompts and taste tests)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Marketing
Description: Marketing conditions (printed material, displays, verbal announcements, prompts and taste tests)
Study: NCT01449474

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient matched instruments
Description: The patients undergo TKA with using patient matched instruments

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jig based instruments
Description: The patients undergo TKA with using jig based instruments
Study: NCT02079974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: 20 mg pravastatin sodium daily for 3 months
Study: NCT03319368

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted gown and glove use
Description: Gown and glove use for high risk care activities in high risk residents
Study: NCT02433522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 500 mg rituximab infusion at the randomization visit and every 6 months for 18 months. Each infusion will be preceded by an infusion of 1000 mg paracetamol, 100 mg methylprednisolone and 5 mg dexchlorpheniramine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02430545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glasdegib
Description: Subjects receive a 100mg oral dose of glasdegib under fasted conditions with washout, then single 100mg oral dose of glasdegib under fasted following dosing to steady state with rifampin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Subjects receive rifampin 600 mg oral dose daily \[Day -6 to day 4\]
Study: NCT01741727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-414
Description: ABT-414 will be administered by intravenous infusion.
Study: NCT01471652

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nutraceutical supplements
Description: 1. CoEnzyme Q10: oral gel capsule bid~2. Acetyl L-carnitine: oral capsule bid~3. Alpha Lipoic Acid: oral tablet qd~4. Docosahexaenoic acid: oral gel capsule bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule form to imitate the following nutraceuticals:~1. Placebo 1: oral gel capsule bid~2. Placebo 2: oral capsule bid~3. Placebo 3: oral tablet qd~4. Placebo 4: oral gel capsule bid
Study: NCT02378870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osteodex
Description: Osteodex 3.0 mg/kg given every two week, maximum 13 times.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03087227

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEUTROSIS
Description: evaluate a shared health information system (NEUTROSIS) for home-hospital management of febrile neutropenia after anti-tumor chemotherapy
Study: NCT02740751

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Still-Tee
Description: The mothers of the babies will receive Still-Tee galactogogue tea

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Still-Tee
Description: The mothers of the babies will receive Still-Tee galactogogue tea
Study: NCT00766727

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GLYDe Dressing
Description: Wound dressing intended to minimize scar formation
Study: NCT01001091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-38583 ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-38583 ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-38583 ophthalmic solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AL-38583 ophthalmic solution vehicle
Description: Inactive ingredients used as a placebo comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone ophthalmic suspension, 0.1%
Study: NCT02612766

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Pure, uncontaminated oats
Study: NCT02395757

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAIA™ (Centervue, Padova, Italy; distributed in France by EDC Lamy, Carvin, France)
Description: An automatic microperimetry exam of the 10° central macular coverage expert test (customized grid) will be performed with the MAIA™ device at each semi-annual follow-up visit.
Study: NCT01750034

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closed method
Description: Subjects will have their wounds managed by covering with gauze and changing this gauze 3 to 7 times per week.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open method
Description: Subjects will have their burns managed by keeping the wounds exposed to the air.
Study: NCT03148834

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Controlled Reperfusion
Description: Patients will be treated in the occluded coronary with a solution of venous blood and Dextran, prior to the Stenting procedure.~Controlled Reperfusion PCI consists of crossing the culprit lesion with guidewire and then advancing a balloon (over the wire) to the distal segment of the culprit vessel. Proximal to the main distal branch, inflate the balloon to low atmospheres, remove the guide wire and inject the solution through the light of the balloon. Then reposition the guidewire, perform angioplasty as usual on the lesion. If there is a large residual thrombus load and at the operator's discretion, change the balloon by a manual thromboaspiration catheter and use it.~Then perform stenting of the lesion. The solution will be given with a 1 cc syringe as a slow bolus, controlling symptoms and ST segment response.~The compounds in solution are venous blood drawn from the patient after administration of heparin and mixed with dextran in a 3/1 ratio.
Study: NCT00071006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736 (Axitinib)
Description: patients were treated with axitinib at starting dose of 5 mg BID continuous dosing.
Study: NCT02705534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: 400 mg, included in a combination pill with 90 mg ledipasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir
Description: 90 mg, included in a combination pill with 400 mg sofosbuvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 1000 mg/day if \<75 kg, 1200 mg/day for \>75 kg. Divided into two daily doses
Study: NCT01092312

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vanguard Knee System with Signature Knee Guide
Description: Use of Signature Knee Guide

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vanguard Knee System with conventional Instruments
Description: Vanguard Knee System with conventional Instruments
Study: NCT02264925

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation with Medtronic Activa PC+S systems
Description: Deep Brain Stimulation of VIM.
Study: NCT02331459

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent training intervention
Description: Intervention characteristics: 24weeks, 5days/week, 60min/session Day 1, 3 and 5 15 min (a) 40 min (b) 5 min (d) Day 2 and 4 15 min (a) 40 min (c) 5 min (d)~Legend:~min. =minutes a = Proprioception exercises, postural sway and dynamic balance, coordination and flexibility of the lumbo-pelvic area b = Aerobic training 65% maximal Heart rate c = Strength training arms and legs d = Stretching

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nutritional intervention
Description: Enrolled patients will receive nutritional information on optimal daily energy intake, ensuring at least a daily protein intake of 1 g. of by kg of weight.~Calcium plus vitamin D (total amount 1200 mg calcium plus 800 IU of vitamin D) Vitamin D will be provided if calcidiol (Cldl) blood levels are lower than 30 ng/ml.~Cldl 20-29 ng/dl it will provide calciferol 20.000 IU every 15 days (3 months) Cldl 10-19 ng/dl it will provide calciferol 20.000 IU every 10 days (3 months) Cldl 1-9 ng/dl it will provide calciferol 20.000 IU every 7 days (3 months)
Study: NCT00581958

Intervention type: OTHER
Intervention: Blood Samples
Description: blood (approximately two 4 ml; equivalent to less than 2 tablespoon) and urine (a cup of urine) samples or testing a total of three times. Blood will be drawn and urine will be collected once before radiation treatment and twice after first radiation treatment.
Study: NCT00360334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection, 5mcg or 10mcg, twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: subcutaneous injection, titrated to target blood glucose level, once a day
Study: NCT02211469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986104
Study: NCT02331459

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Description: Enrolled patients will receive nutritional information on optimal daily energy intake, ensuring at least a daily protein intake of 1 g. of by kg of weight.~Calcium plus vitamin D (total amount 1200 mg calcium plus 800 IU of vitamin D) Vitamin D will be provided if calcidiol (Cldl) blood levels are lower than 30 ng/ml.~Cldl 20-29 ng/dl it will provide calciferol 20.000 IU every 15 days (3 months) Cldl 10-19 ng/dl it will provide calciferol 20.000 IU every 10 days (3 months) Cldl 1-9 ng/dl it will provide calciferol 20.000 IU every 7 days (3 months)
Study: NCT02100215

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Common readings and educational handouts
Description: Participants in all groups have common readings related to policies for nursing care in acute care facilities. There will be additional handouts related to performing safety checks and a focused physical assessment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Common readings and educational handouts
Description: Participants in all groups have common readings related to policies for nursing care in acute care facilities. There will be additional handouts related to performing safety checks and a focused physical assessment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Common readings and educational handouts
Description: Participants in all groups have common readings related to policies for nursing care in acute care facilities. There will be additional handouts related to performing safety checks and a focused physical assessment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expert Modeling
Description: 70 minutes of expert modeling videos

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Voice Over Power Point
Description: 60 minutes of Voice Over PowerPoint presentations
Study: NCT03147209

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching
Description: This intervention will consist of health coaching, goal setting and self directed activities to improve strength and balance.
Study: NCT02474420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: Deferasirox administered per standard of care by the treating physician
Study: NCT00860171

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Autologous stem cells given via central catheter
Study: NCT00910000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study: NCT00860171

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Iodine I 131 Monoclonal Antibody BC8
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03009422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local application pentostam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intra-lisional pentostam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fractional CO2 laser
Study: NCT03261609

Intervention type: OTHER
Intervention: preterm birth
Description: The study compares young adult subjects born premature (\< 29 weeks) versus term (-\> 37 weeks)

Intervention type: OTHER
Intervention: preterm birth
Description: The study compares young adult subjects born premature (\< 29 weeks) versus term (-\> 37 weeks)
Study: NCT02741141

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New partograph based on the studies of Neal and Lowe
Description: The partograph designed by Neal and Lowe includes an action line which if crossed permits an active management of labour.~Eventually, the only difference between the two arms is the moment when the active management of labour is started.~The oxytocin is administrated according to the department protocol.
Study: NCT02211469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT04131439

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed Tomography and Magnetic resonance imaging
Description: Preoperative imaging for patients undergoing cochlear implants
Study: NCT04002297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zanubrutinib
Description: Administered as two 80 mg capsules by mouth twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bendamustine
Description: Administered intravenously at a dose of 90 mg/m2/day on Days 1 and 2 of Cycles 1 to 6

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: Administered intravenously at a dose of 375 mg/m2 on Day 1 of Cycles 1 to 6
Study: NCT02741141

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classical partograph
Description: Classical partograph used as standard care
Study: NCT00961363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: sitagliptin 100 mg per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03315312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoride Varnishes
Description: Fluoride varnish is randomly applied on randomly selected first permanent molar. This study uses a natural clinical setting, where clinicians use methods and procedures that are routinely applied in public dental clinics.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fissure Sealants
Description: Resin-based fissure sealant is applied on contra-lateral first permanent molar and each child serves as its own control. This study uses a natural clinical setting, where clinicians use methods and procedures that are routinely applied in public dental clinics.
Study: NCT04206371

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Defibrillator threshold testing
Description: Under general or local anesthesia. Induction of Ventricular Fibrillation or R-wave synchronized shock
Study: NCT01994265

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin once daily, at fast, targeting INR between 2 and 3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran
Study: NCT04002297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Administered intravenously at a dose of 375 mg/m2 on Day 1 of Cycles 1 to 6
Study: NCT01598909

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arnica
Description: Application of Arnica ointment periorbitally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ointment
Description: Application of Arnica ointment, twice a day, for the period of one week.
Study: NCT02472301

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cowpeas complementary food
Description: cowpeas supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: corn-soy flour
Description: Corn-soy flour supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: common bean complementary food
Description: common bean supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
Study: NCT03354273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PET MPI
Description: Flurpiridaz (18F) Injection. All participants received 2 IV boluses of Flurpiridaz (18F) Injection in a large peripheral vein: 1 at rest and 1 during stress. The dosages of Flurpiridaz (18F) Injection administered at rest and during stress conditions did not exceed a total of 14 mCi (520 MBq) for an individual participant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPECT MPI
Description: SPECT imaging was used 99mTc-based myocardial tracers. SPECT agents utilised for the purposes of this clinical study was administered as per American Society of Nuclear Cardiology or European Association of Cardiovascular Imaging standards, where applicable. All participants undergone SPECT MPI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacological stress agents
Description: Pharmacologic stress agents were restricted to the following 3 agents, as permitted by local marketing authorisations and availability: adenosine, dipyridamole, and regadenoson. Administration was through an IV line.
Study: NCT02211469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03445416

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POL arm
Description: A popular opinion leader intervention designed to increase routine vaccination among young black men who have sex with men.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparison arm
Description: A popular opinion leader intervention designed to increase routine vaccination among young black men who have sex with men.
Study: NCT00508742

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent Pneumococcal Conjugate Vaccine
Description: 1 dose at 2, 4, 6 and 12 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 7 valent pneumococcal conjugate vaccine
Description: 1 dose at 2, 4, 6 and 12 months of age
Study: NCT01730222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: cisplatin at 30 mg/m2 on days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: capecitabine at 1250 mg/ m2 days 1-28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: gemcitabine at 800 mg/ m2 on days 1 and 15 in arm A; at 1000 mg/m2 on days 1, 8 and 15 in arm B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Description: gemcitabine at 800 mg/ m2 on days 1 and 15 in arm A; at 1000 mg/m2 on days 1, 8 and 15 in arm B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: nab-paclitaxel at the recommended phase II dose day 1 and 15 in arm A; at 125 mg/m2 on days 1, 8 and 15 in arm B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel
Description: nab-paclitaxel at the recommended phase II dose day 1 and 15 in arm A; at 125 mg/m2 on days 1, 8 and 15 in arm B
Study: NCT03428139

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulsed radiofrequency
Description: Each patient in this group was treated with PRFT on the affected DRG at 42°C for 120 seconds.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pulsed radiofrequency plus alpha lipoic acid
Description: Each patient in this group was treated with PRFT as in group I plus oral alpha lipoic acid (ALA) 600 mg (Thiotacid 600 mg, EVA PHARMA, Egypt) three times per day (1800mg/day) for 3 weeks then 600mg once daily for 2 weeks.
Study: NCT01424657

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERCP
Description: Endoscopic retrograde cholangiopancreatography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRCP
Description: magnetic resonance cholangiopancreatography
Study: NCT00483119

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous immunoglobulin
Description: Gamunex 10% 500/mg/kg/day x four days per cycle total of four cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous immunoglobulin
Description: Gamunex 10% 500/mg/kg/day x four days per cycle total of four cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: cyclophosphamide dose of 2mg/kg/day divided into three-times daily oral administration